Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

clinical trial

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT01270438

P6099clinical trial phasephase II clinical trialQ42824440
P582end time2011-08-01
P1050medical conditionadenocarcinomaQ356033
P2899minimum age18
P1132number of participants0
P4844research interventioncalcium oxalateQ412399
bevacizumabQ413299
leucovorin calciumQ27077063
fluorouracilQ238512
P6153research siteMayo ClinicQ1130172
Memorial Sloan Kettering Cancer CenterQ1808012
P580start time2010-12-01
P8363study typeinterventional studyQ78089383
P1476titleA Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)

Search more.